Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Vitalik: Ethereum's mission is to connect Eastern and Western communities, and plans to achieve 10 times expansion next year

Vitalik: Ethereum's mission is to connect Eastern and Western communities, and plans to achieve 10 times expansion next year

CointimeCointime2025/09/13 14:36
By:Cointime

On September 13th, Ethereum co-founder Vitalik Buterin took the stage at EthTokyo 2025 and delivered a speech, stating that he firmly believes that Layer 2 solutions are the future development direction of Ethereum. He further proposed an ambitious goal: Ethereum plans to achieve a 10x capacity increase next year, while maintaining decentralization and security, by improving network throughput and accessibility.

Vitalik particularly emphasized the role of Asia. China developed an early PyEthereum client, volunteers translated the whitepaper and documentation into multiple languages, and community efforts have propelled Ethereum globally. He compared the development styles of Chinese and Japanese developers: Chinese projects progress rapidly and on a large scale, while Japanese developers are more adept at trying new technologies. Looking ahead, Vitalik called for more researchers and application developers to join, rather than relying solely on the core team. He encouraged Asian developers to focus on efficiency and security, and believes that AI will become an important learning tool.

New technologies often "reset" ecosystems, such as the breakthrough brought by zero-knowledge proofs. Vitalik predicted that the 2030s will usher in a new technological paradigm. Vitalik reiterated that Ethereum's mission is to connect Eastern and Western communities. In terms of funding models, he believes that the global advantage outweighs traditional VCs, and proposed that the future should combine new funding models with DAO governance to create a more open and transparent financial mechanism.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Wall Street Stands Guard as Bessent Strikes Again: Aftereffects of August's "Treasury Turnaround" Persist, November Refinancing Notice Could Be the Next Flashpoint

As the US Treasury prepares to update its debt management plan in November, key clues may emerge on Friday.

智通财经•2026/10/16 01:06

"Coca-Cola belief" never goes out of style! KFC in America says goodbye to Pepsi and embraces Coca-Cola (KO.US); Buffett-style "boring investment" returns to the spotlight

KFC has chosen Coca-Cola as its soda supplier in the United States, abandoning its long-term partner Pepsi. As of the close of the U.S. stock market on Thursday, Coca-Cola's (KO.US) stock price reached a record high, defying the ongoing declines in global tech stocks, especially in the semiconductor and broad AI computing sectors.

智通财经•2026/10/16 01:06

AI financing concerns weigh heavily on chip stocks, global tech sector has lost over $1 trillion this week

Multiple pressures, including rising expectations of a Federal Reserve rate hike and increasing AI financing costs, have led to a massive sell-off in global tech stocks this week. The combined market value of the world's top 20 AI and semiconductor stocks has evaporated by more than $1 trillion, and the semiconductor ETF (SOXX) has recorded its longest losing streak in 11 years. On Thursday, SK Hynix continued to plunge by over 10% in a single day, while Nvidia, Samsung, and SoftBank were not spared.

华尔街见闻•2026/10/16 00:51

Safe Haven Amid AI Crash! Major Pharmaceutical Stocks Approach Historic Highs

Amid concerns over AI capital expenditures, funds are seeking a "certainty premium." State Street Healthcare ETF reached a record high. Eli Lilly and AbbVie are both approaching their historical highest closing prices, while Gilead and Amgen have surged 7.7% and 7.2% respectively over the past five days. Eli Lilly continues to bet on the future through its GLP-1 dominance and 40 M&A deals totaling $20 billion. AbbVie's core drug Skyrizi has shown positive data for its new subcutaneous formulation, which is expected to extend its patent and drive additional sales.

华尔街见闻•2026/10/16 00:37
Safe Haven Amid AI Crash! Major Pharmaceutical Stocks Approach Historic Highs